NPPA fixed price of 8 formulations including FDCs of Statins, Glifozins

Published On 2021-02-09 07:07 GMT | Update On 2021-02-09 07:25 GMT

New Delhi: Through a recent notice, the National Pharmaceutical Pricing Authority, the pharma price regulator has fixed the price of 8 formulations.Prominent ones whose price have been fixed include Glenmarks/Intas's Remoglifozin and Metformin Combination, Sun Pharma's Rosuvastatin + Aspirin combination, as well as Aristo's Paracetamol + Mefenamic Acid SuspensionThis comes after in exercise...

New Delhi: Through a recent notice, the National Pharmaceutical Pricing Authority, the pharma price regulator has fixed the price of 8 formulations.

Prominent ones whose price have been fixed include Glenmarks/Intas's Remoglifozin and Metformin Combination, Sun Pharma's Rosuvastatin + Aspirin combination, as well as Aristo's Paracetamol + Mefenamic Acid Suspension

This comes after in exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority NPPA), fixed, the price as specified in column (6) of the table herein below as the retail price, exclusive of Goods and Services Tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;

Table

Sl. No.	Name of the Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)
1.	Rosuvastatin + Aspirin Capsule	Each Capsule contains: Rosuvastatin Calcium IP eq. to Rosuvastatin 20mg Aspirin IP 75mg (as enteric coated)	1 Capsule	M/s Sun Pharma Laboratories Limited	8.33
2.	Escitalopram + Clonazepam Tablet	Each film coated tablet contains: Escitalopram Oxalate IP eq. to Escitalopram 20mg, Clonazepam IP 0.5mg	1 Tablet	M/s Sun Pharma Laboratories Limited	18.19
3.	Amlodipine & Extended Release Metoprolol Succinate tablet (AMLONG MT 5/25)	Each film coated bilayered Tablet contains: Amlodipine Besilate IP eq. to Amlodipine 5mg Metoprolol Succinate IP 23.75mg eq. to Metoprolol Tartrate 25mg (As Extended Release form)	1 Tablet	M/s Micro Labs Limited	6.15
4.	Remogliflozin etabonate and Metformin hydrochloride tablet	Each film coated Tablet contains: Remogliflozin etabonate 100mg Metformin hydrochloride IP 1000mg	1 Tablet	M/s Glenmark Pharmaceuticals Ltd. / M/s Intas Pharmaceuticals Ltd.	13.18
5.	Remogliflozin etabonate and Metformin hydrochloride tablet	Each film coated Tablet contains: Remogliflozin etabonate 100mg Metformin hydrochloride IP 500mg	1 Tablet	M/s Glenmark Pharmaceuticals Ltd. / M/s Intas Pharmaceuticals Ltd.	11.44
6.	Azathioprine Tablet	Each film coated Tablet contains: Azathioprine IP 100mg	1 Tablet	M/s RPG Life Sciences Limited	8.69
7.	Paracetamol + Mefenamic Acid Suspension	Each 5ml contains: Paracetamol IP 125mg, Mefenamic Acid IP 50mg	1 ML	M/s Aristo Pharmaceuticals Pvt. Ltd.	0.58
8.	Paracetamol + Mefenamic Acid Suspension	Each 5ml contains: Paracetamol IP 250mg, Mefenamic Acid IP 100mg	1 ML	M/s Aristo Pharmaceuticals Pvt. Ltd.	0.66

The NPPA in its note further added

(a) The manufacturer of above mentioned formulations i.e. "new drug" under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.

(b) The manufacturer may add Goods and Services Tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table.

(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.

(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he/she carries on business in a manner so as to be easily accessible to any person wishing to consult the same.

(e) The above mentioned retail price is applicable only to the individual manufacturer/marketer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.

(f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.

(g) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

NPPA fixed price of 8 formulations including FDCs of Statins, Glifozins

Similar News